I think that Telstra Group Ltd (ASX: TLS) is one of the most appealing ASX blue-chip shares to consider for passive income because of how much the business is paying.

As a very profitable business, Telstra is rewarding investors with large and growing dividend payments.

Dividends aren’t guaranteed, of course, but in a defensive industry like telecommunications, the payouts are more reliable and resilient than in many other sectors, in my view.

Let’s get into how Telstra could deliver $1,000 of annual passive income in 2027.

Telstra dividend projection

The business delivered strong dividend growth in FY26, increasing its annual dividend per share by 10.5% to 21 cents. Not many ASX blue-chip shares grew their payout by that much in FY26.

Things could get even better for shareholders in the 2027 financial year, and that’s what I think investors should focus on for the current financial year. FY26 is now the past.

According to CommSec, analysts are now projecting the annual dividend per share could grow to 22 cents per share. That would be a grossed-up dividend yield of 6.5%, including franking credits, at the time of writing.

Not many ASX blue-chip shares are offering that sort of potential yield, with further growth projected to come in the following financial year (FY28).

What would it take for $1,000 of passive income in 2027?

The amount required for $1,000 of annual dividends in FY27 depends on whether franking credits are included in the income.

With a passive income projection of 22 cents per share in the 2027 financial year, it would require 4,546 Telstra shares to generate that much dividend cash.

If we include franking credits as part of the dividend income, it would take 3,182 Telstra shares to reach the $1,000 grossed-up dividend income goal.

Is this a good time to invest in Telstra shares?

Analysts are largely positive or neutral on the business right now. According to CommSec’s collation of expert ratings, there are currently seven buys, eight holds, and one sell rating on the business.

Telstra expects both of its measures of operating profit (underlying EBITDAaL and cash EBIT) to rise in the single digits in FY27. Underlying EBITDAaL could come between $8.5 billion and $8.8 billion, while cash EBIT could reach between $4.75 billion and $4.95 billion.

While faster growth would be preferred, the company continues to demonstrate its ability to grow earnings, whether that’s during good times or not.

Australia’s ongoing digitalisation and growing population are both demand drivers for connection to the company’s mobile network or its fibre network, which can help earnings and the dividend in the coming year.

The post How much must I invest in Telstra shares to earn a $1,000 passive income in 2027? appeared first on The Motley Fool Australia.

More reading

• Telstra vs Woodside: Which ASX dividend stock comes out on top?
• A leading fund just bought these top ASX 200 shares
• How much superannuation do I need to earn $56,000 per year in passive income?
• Buy, hold, sell: Deep Yellow, SGH, Telstra shares
• With $2.4 billion in FY26 profits, are Telstra shares a good buy today?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX health technology company Blinklab Ltd (ASX: BB1) is entering an interesting phase, broker Morgans believes, with several share price catalysts soon to emerge.

New technology opening up a large market

Blinklab produces smartphone software to diagnose conditions such as autism and ADHD. Morgans noted that readouts from four exploratory programs are soon to be published.

Blinklab has almost fully recruited participants for a pivotal study for autism, with Morgans saying this should be completed by the end of the year, with submission to the US Food and Drug Administration expected in the first quarter of calendar 2027.

Morgans added:

BB1’s technology has broad applications across additional indications (adult autism, dementia detection, ketamine-based pharma intervention) and preliminary data is expected to read out over the next 12 months adding to the cadence of news flow. Recently, BB1’s European ADHD study delivered positive results. A US pilot is due to start in 2QCY27, ahead of a pivotal study mirroring the autism path. We agree with management that this presents a significantly larger commercial opportunity than autism spectrum disorder.

The company also recently announced a major appointment, with Dr Raphael Bernier joining the board.

Dr Bernier was the former clinical lead for mental health at Apple Health. The company said he brought first-hand experience translating clinical science into digital products at a global scale.

Blinklab said at the time:

Dr Bernier brings a rare combination of clinical practice, internationally recognised research leadership and commercial product-development experience. His appointment is intended to deepen the Board’s expertise as BlinkLab progresses its pivotal U.S. FDA 510(k) program for BlinkLab Dx1 and prepares for clinical adoption and commercialisation in the United States, subject to regulatory clearance. Dr Bernier recently retired from Apple Health, where he led the clinical development of the Mental Wellbeing app for iPhone, iPad and Apple Watch. He also conducted early-stage research across released and unreleased products in the Apple ecosystem and supported the rollout of additional products relating to child development and cognitive accessibility.

Morgans said there were significant market opportunities in the diagnosis of autism and ADHD, and Blinklab also had the opportunity to expand into other conditions.

Shares looking cheap

The broker has a 12-month price target of $1.76 on Blinklab shares compared to 66 cents currently.

If achieved, this would be a 166% return. The shares are well down from their 12-month high of $1.10.

Blinklab is valued at $114.6 million.

The post This ASX health technology company could more than double in value: Broker appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Monday
• Tech shares shine while ASX 200 plunges to 4-month low
• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Friday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Apple. The Motley Fool Australia has recommended Apple. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The big four banks have traditionally been seen as safe havens for Australian investors. However, a new research report from broker Jarden argues that they are all overvalued at current share prices.

Jarden only has an overweight recommendation on ANZ Group Holdings Ltd (ASX: ANZ). Meanwhile, it has sell ratings on Commonwealth Bank of Australia (ASX: CBA), National Australia Bank Ltd (ASX: NAB) and Westpac Banking Corporation (ASX: WBC).

Federal Budget having an impact

The broker argues that the federal government’s changes to capital gains tax and negative gearing rules for property investors will at least halve the rate of home loan growth, which could have implications for dividend policies at the banks.

Jarden said Macquarie Group Ltd (ASX: MQG) continues to outperform the big four banks with its simplified digital offerings.

The broker also said AI threatens to change the way people interact with banking, and inertia may no longer be enough to retain customers.

While Jarden prefers ANZ to the other banks with its overweight rating, its price target of $35.50 is still below the current level of $37.36.

ANZ is also paying a 4.5% dividend yield.

The bank recently announced that its cash profit for the quarter ended 30 June was up just 1% on the quarterly average of the half-year ended 31 March.

At the time, ANZ Chief Executive Officer Nuno Matos said:

As we release our third quarter update, we remain on track to meet our Return on Tangible Equity and Cost-to-Income targets. In the quarter, we continued to improve productivity, margins and business volumes, including accelerating growth in business banking and returning home lending to system growth. Beyond our immediate priorities, we are investing now in customer experience, propositions, channel uplift and transaction banking. This will position us well for the second phase of our strategy beyond 2027, to accelerate growth and outperform the market.

Commonwealth Bank could drop sharply

Regarding Commonwealth Bank, Jarden is predicting a very steep share price fall from $151.18 currently to $90.

When releasing its FY26 results, CBA warned of difficult times ahead.

It said:

The Australian economy has remained resilient, supported by historically low unemployment and longer-term investment. However growth is slowing, with higher interest rates and inflation placing uneven pressure on household incomes and economic activity. Housing activity has softened from a high base. Application volumes appear to have stabilised in recent weeks. Businesses continue to manage higher input costs and supply uncertainty.

For National Australia Bank, Jarden is forecasting a share price of $29, compared to $38.55 currently. Meanwhile, for Westpac, it is predicting its share price to fall from $34.26 (at the time of writing) to $31.

The post How much could the big 4 banks’ share prices fall? appeared first on The Motley Fool Australia.

More reading

• ANZ vs AMP: Which ASX blue chip is the better buy this month?
• How much superannuation do I need to earn $56,000 per year in passive income?
• Fortescue vs National Australia Bank: Which ASX blue chip is the better buy this month?
• Buy, hold, sell: CBA, Capstone Copper, Codan shares
• Why I’d buy CBA and Coles shares in October

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.